1Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
2Nickenig G, Harrison G. The AT (1)-type angiotensin recep- tor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
3Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6): 881-900.
4Nickenig G. Central role of the AT (1)-receptor in athero- sclerosis. J Hum Hypertens 2002; 16 Suppl 3: S26-S33.
5Erwig LP, Kluth DC, Rees A J, Macrophages in renal inflam- mation. Curr Opin Nephrol Hypertens 2001; 10:341-347.
6Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153.
7Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001; 161: 1492-1499.
8Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. An- giotensin II AT 1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 35: 1726- 1731.
9Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hof- mayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen spe- cies generation in leukocytes, nuclear factor-rd3, in mononu- clear cells of normal subjects: evidence of an antiinflamma- tory action. J Clin Endocrinol Metab 2003; 88: 4496-4501.
10Sanz-Rosa D, Oubina ME Cediel E, De Las Heras N, Vegazo O, Jimenez J, Lahera V, Cachofeiro V. Effect of AT1 receptor antagonism on vascular and circulating inflammatory media- tors in SHR: role of NF-κB/I-κB system. Am J Physiol Heart Circ Physiol 2005; 288:H111-H115.
